Could this tarnished pot stock possibly stage a turnaround? Most don't think so.
Is the optimism surrounding this insulin pump maker justified?
Livongo might be up after beating expectations, but does that make this stock an automatic buy?
What should investors think of Sientra after its impressive Q3 results?
Which of these two cannabis companies will reign supreme in the future?
While good publicity for the cannabis industry, how big of a deal is this for Canopy Growth?
Prospects for Amarin's omega-3 drug seem strong, but does that make the stock a buy?
There are some highly promising diabetes treatments entering the market that investors should know about.
These three healthcare companies have a lot of good things going for them.
While the results are promising, are they enough to threaten Merck's cancer superdrug Keytruda?
Investors should keep an eye on these promising pot producers.
Investors were pleasantly surprised by an unexpected turnaround in aducanumab's clinical trial data, but how justified is the market's optimism?
What should investors think of this piece of news?
What should investors think of this biotech stock and its signature drug candidate Andexxa?
New breast cancer trial results could prove to be a major catalyst for the stock.
The company has given back most of its 2019 gains, but does this change its previously bullish appraisal?
Amid concerns about its $63 billion Allergan buyout, is now a good time to invest in the pharmaceutical giant?
Does this mean anything for the pharmaceutical giant's long-term outlook?
This energy giant is a staple in many portfolios, but what does the future hold?
The battered cannabis giant could become the dominant player in the athletics market.